Lesley C. Kaye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lesley C. Kaye has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Cornelia Drees
Mayo Clinic Phoenix Arizona USA
2 shared publications - Jerzy P. Szaflarski
Department of Neurology University of Alabama at Birmingham Birmingham Alabama USA
2 shared publications Adithya Sivaraju
1 shared publication- Aimee Bui
College of Osteopathic Medicine Rocky Vista University Englewood Colorado USA
1 shared publication Alexandra Danciutiu
Department of Neurology University of Colorado School of Medicine Aurora Colorado USA
1 shared publicationAline Herlopian
1 shared publication
Latest Publications
- Open Access
- 12 May 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (9) , e214875
Postapproval Study for Brain-Responsive Neurostimulation for Drug-Resistant Focal Epilepsy
Background and ObjectivesNeuromodulation therapies are approved for the treatment of focal epilepsy based on data from randomized controlled trials (RCTs). After approval of a responsive direct bra...
- 12 May 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (9) , e214875
Open AccessPostapproval Study for Brain-Responsive Neurostimulation for Drug-Resistant Focal Epilepsy
Background and ObjectivesNeuromodulation therapies are approved for the treatment of focal epilepsy based on data from randomized controlled trials (RCTs). After approval of a responsive direct bra...
- Open Access
Delayed and deferred surgery associated with cenobamate use in people with drug‐resistant focal epilepsy
Objective: Cenobamate has been shown to be an effective antiseizure medication for some patients with drug‐resistant focal epilepsy being considered for epilepsy surgery. This retrospective single‐center study evaluated whether surgery was obtained within 12 months for patients who received cenobamate as a treatment during the presurgical evaluation and those who did not, comparing across years before and after cenobamate approval. Methods: Patients undergoing surgical evaluation for drug‐resistant focal epilepsy at the University of Colorado during 2018 and 2023 who had 12 months of follow‐up data were analyzed. Comparison years were also chosen to avoid the confounding effect of the COVID‐19 pandemic on surgical volume (2020–2021). This allowed for comparison times before and after cenobamate's US Food and Drug Administration approval. The primary outcome (surgery within 12 months) was modeled with potential explanatory variables using multiple logistic regression. A p ‐value of <.05 was considered significant. Results: After controlling for potentially confounding clinical and demographic variables, cenobamate use during the presurgical evaluation period was associated with .13 lower odds of surgery within 12 months compared to not being prescribed this medication (95% confidence interval [CI] = .04–.42, p < .001). Being Hispanic or Latino was significantly associated with .23 lower odds of surgery within 12 months compared to patients who did not report being Hispanic or Latino (95% CI = .09–.61, p = .003). Year of evaluation (2023 vs. 2018), education level, age, and sex did not have significant associations with undergoing surgery within 12 months. Significance: Patients with drug‐resistant focal epilepsy undergoing evaluation for epilepsy surgery may benefit from cenobamate. In this study, patients who received cenobamate during the presurgical evaluation were less likely to undergo surgery within 12 months. The delay to surgery identified among Hispanic and Latino patients suggests potential barriers to care in this patient population warranting further investigation.
Open AccessDelayed and deferred surgery associated with cenobamate use in people with drug‐resistant focal epilepsy
Objective: Cenobamate has been shown to be an effective antiseizure medication for some patients with drug‐resistant focal epilepsy being considered for epilepsy surgery. This retrospective single‐center study evaluated whether surgery was obtained within 12 months for patients who received cenobamate as a treatment during the presurgical evaluation and those who did not, comparing across years before and after cenobamate approval. Methods: Patients undergoing surgical evaluation for drug‐resistant focal epilepsy at the University of Colorado during 2018 and 2023 who had 12 months of follow‐up data were analyzed. Comparison years were also chosen to avoid the confounding effect of the COVID‐19 pandemic on surgical volume (2020–2021). This allowed for comparison times before and after cenobamate's US Food and Drug Administration approval. The primary outcome (surgery within 12 months) was modeled with potential explanatory variables using multiple logistic regression. A p ‐value of <.05 was considered significant. Results: After controlling for potentially confounding clinical and demographic variables, cenobamate use during the presurgical evaluation period was associated with .13 lower odds of surgery within 12 months compared to not being prescribed this medication (95% confidence interval [CI] = .04–.42, p < .001). Being Hispanic or Latino was significantly associated with .23 lower odds of surgery within 12 months compared to patients who did not report being Hispanic or Latino (95% CI = .09–.61, p = .003). Year of evaluation (2023 vs. 2018), education level, age, and sex did not have significant associations with undergoing surgery within 12 months. Significance: Patients with drug‐resistant focal epilepsy undergoing evaluation for epilepsy surgery may benefit from cenobamate. In this study, patients who received cenobamate during the presurgical evaluation were less likely to undergo surgery within 12 months. The delay to surgery identified among Hispanic and Latino patients suggests potential barriers to care in this patient population warranting further investigation.
- Open Access
- 3 April 2025
- Published by Elsevier in Brain Stimulation
- Vol. 18 (3) , 738-744
Aperiodic activity as a biomarker of seizures and neuromodulation
- 3 April 2025
- Published by Elsevier in Brain Stimulation
- Vol. 18 (3) , 738-744
Open AccessAperiodic activity as a biomarker of seizures and neuromodulation
- Open Access
- 16 March 2024
- Published by Elsevier in Brain Stimulation
- Vol. 17 (2) , 382-391
Feasibility study of microburst VNS therapy in drug-resistant focal and generalized epilepsy
- 16 March 2024
- Published by Elsevier in Brain Stimulation
- Vol. 17 (2) , 382-391
Open AccessFeasibility study of microburst VNS therapy in drug-resistant focal and generalized epilepsy
- Open Access
- 1 January 2014
- Published by Wiley in Case Reports in Oncological Medicine
- Vol. 2014, 1-4
Small Cell Lung Cancer Presenting as Severe Thrombocytopenia and Refractory Hypokalemia
A 70-year-old female with a history of mild cirrhosis was referred by her primary care provider for a platelet count of 36,000/μL which had dropped from 47,000/μL in a week along with mild pain in extremities. Serum potassium was low (2.9 mEq/L) in spite of the patient being recently started on potassium supplement on outpatient for hypokalemia. Initially thrombocytopenia was attributed to cirrhosis. However, platelet counts continued to drop to a nadir of 9000/μL in spite of several platelet transfusions. Hypokalemia was refractory to potassium supplements. Subsequent bone marrow biopsy revealed extensive marrow necrosis with a focus of small cell tumor cells of pulmonary origin. CT scan of the chest showed a spiculated left lung mass. The ACTH level was high, with normal rennin and aldosterone levels. The patient likely had ectopic ACTH syndrome from small cell lung cancer. She died within few days of diagnosis. Severe thrombocytopenia and refractory hypokalemia can rarely be initial presentations of small cell lung cancer. Thrombocytopenia should prompt an evaluation for bone marrow metastases and a search for undiagnosed systemic malignancy. In severe cases of metastases, bone marrow necrosis can be present. Refractory hypokalemia can be the sole presentation of ectopic ACTH production.
- 1 January 2014
- Published by Wiley in Case Reports in Oncological Medicine
- Vol. 2014, 1-4
Open AccessSmall Cell Lung Cancer Presenting as Severe Thrombocytopenia and Refractory Hypokalemia
A 70-year-old female with a history of mild cirrhosis was referred by her primary care provider for a platelet count of 36,000/μL which had dropped from 47,000/μL in a week along with mild pain in extremities. Serum potassium was low (2.9 mEq/L) in spite of the patient being recently started on potassium supplement on outpatient for hypokalemia. Initially thrombocytopenia was attributed to cirrhosis. However, platelet counts continued to drop to a nadir of 9000/μL in spite of several platelet transfusions. Hypokalemia was refractory to potassium supplements. Subsequent bone marrow biopsy revealed extensive marrow necrosis with a focus of small cell tumor cells of pulmonary origin. CT scan of the chest showed a spiculated left lung mass. The ACTH level was high, with normal rennin and aldosterone levels. The patient likely had ectopic ACTH syndrome from small cell lung cancer. She died within few days of diagnosis. Severe thrombocytopenia and refractory hypokalemia can rarely be initial presentations of small cell lung cancer. Thrombocytopenia should prompt an evaluation for bone marrow metastases and a search for undiagnosed systemic malignancy. In severe cases of metastases, bone marrow necrosis can be present. Refractory hypokalemia can be the sole presentation of ectopic ACTH production.